Compugen signs research agreement with Teva Pharmaceutical

Aug 28 (Reuters) - Israel-based Compugen Ltd (CGEN.O) said it signed a research agreement with Teva Pharmaceutical Industries Ltd (TEVA.O) related to CGEN-54, Compugen's drug candidate for chronic inflammatory diseases.

The agreement covers both an initial research collaboration and an option to Teva for a worldwide exclusive development and commercialization license, the biotechnology company said in a statement.

(Reporting by Sweta Singh in Bangalore)

((Editing by Christina Pantin; Reuters messaging: sweta.singh.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800) Keywords: Compugen AGREEMENT/TEVA

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2968